IL146565A0 - A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5 - Google Patents

A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5

Info

Publication number
IL146565A0
IL146565A0 IL14656500A IL14656500A IL146565A0 IL 146565 A0 IL146565 A0 IL 146565A0 IL 14656500 A IL14656500 A IL 14656500A IL 14656500 A IL14656500 A IL 14656500A IL 146565 A0 IL146565 A0 IL 146565A0
Authority
IL
Israel
Prior art keywords
seq
insulin
binds
tumors
pharmaceutical composition
Prior art date
Application number
IL14656500A
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL146565A0 publication Critical patent/IL146565A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14656500A 1999-07-19 2000-07-19 A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5 IL146565A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449599P 1999-07-19 1999-07-19
PCT/CA2000/000853 WO2001005435A2 (en) 1999-07-19 2000-07-19 Antisense therapy for hormone-regulated tumors

Publications (1)

Publication Number Publication Date
IL146565A0 true IL146565A0 (en) 2002-07-25

Family

ID=22508861

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14656500A IL146565A0 (en) 1999-07-19 2000-07-19 A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
IL146565A IL146565A (en) 1999-07-19 2001-11-19 A pharmaceutical preparation containing an antisense oligonucleotide that binds to the 5-protein compound of an insulin-like growth factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146565A IL146565A (en) 1999-07-19 2001-11-19 A pharmaceutical preparation containing an antisense oligonucleotide that binds to the 5-protein compound of an insulin-like growth factor

Country Status (13)

Country Link
US (1) US7297684B1 (de)
EP (1) EP1200579B1 (de)
JP (1) JP5121106B2 (de)
KR (2) KR100779752B1 (de)
AT (1) ATE393220T1 (de)
AU (1) AU772480B2 (de)
CA (1) CA2375467C (de)
DE (1) DE60038680T2 (de)
HU (1) HU228465B1 (de)
IL (2) IL146565A0 (de)
NO (1) NO332388B1 (de)
NZ (1) NZ516701A (de)
WO (1) WO2001005435A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
MXPA05003551A (es) 2002-10-02 2005-10-19 Univ British Columbia Composiciones y metodos para el tratamiento de prostata y otros canceres.
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
EP1667731B1 (de) 2003-10-01 2013-05-22 The University Of British Columbia Bispezifisches oligonucleotid zur behandlung von malignen zns-erkrankungen
KR20220012881A (ko) * 2004-07-23 2022-02-04 퍼시픽 에지 리미티드 방광암 검출용 소변 표지
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
JP5390179B2 (ja) * 2008-12-24 2014-01-15 花王株式会社 Ｉｇｆｂｐ−５発現抑制剤
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
WO2025234704A1 (ko) * 2024-05-07 2025-11-13 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드 및 항암제를 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546110B1 (de) 1990-08-28 2001-11-14 Chiron Corporation Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
EP0546074B1 (de) 1990-08-28 2001-11-14 Chiron Corporation Genetisches igfbp-5 rodierendes material
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Also Published As

Publication number Publication date
IL146565A (en) 2012-02-29
US7297684B1 (en) 2007-11-20
NZ516701A (en) 2004-11-26
NO20020259D0 (no) 2002-01-17
HU228465B1 (en) 2013-03-28
KR20020033735A (ko) 2002-05-07
KR100779752B1 (ko) 2007-11-27
NO332388B1 (no) 2012-09-10
NO20020259L (no) 2002-01-17
AU6144500A (en) 2001-02-05
DE60038680T2 (de) 2009-05-07
CA2375467A1 (en) 2001-01-25
KR20070036180A (ko) 2007-04-02
DE60038680D1 (de) 2008-06-05
ATE393220T1 (de) 2008-05-15
JP5121106B2 (ja) 2013-01-16
AU772480B2 (en) 2004-04-29
EP1200579B1 (de) 2008-04-23
EP1200579A2 (de) 2002-05-02
JP2003504418A (ja) 2003-02-04
WO2001005435A2 (en) 2001-01-25
CA2375467C (en) 2013-10-29
KR100856475B1 (ko) 2008-09-08
HUP0201868A2 (en) 2002-12-28
WO2001005435A3 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
IL146565A0 (en) A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
IL144975A0 (en) A composition containing an antisense oligonucleotide
AU4339997A (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2000008141A2 (en) Short oligonucleotides for the inhibition of vegf expression
US6071891A (en) Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
AU9092001A (en) Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
Rubenstein et al. Antisense oligonucleotide intralesional therapy for human PC‐3 prostate tumors carried in athymic nude mice
EP0668782A1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von kreb
Hung et al. Antisense oligodeoxynucleotides targeted against different regions of CyclinD1 mRNA may exert different inhibitory effects on cell growth and gene expression
AU646643B2 (en) Antisense oligonucleotides to C-ABL proto-oncogene
JP2002509692A5 (de)
EP1282641A4 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
Luster et al. Modification of tumor cell proliferation and peptide hormone secretion
Katoh et al. Induction of anchorage independent growth of normal fibroblasts by growth factors
US7491816B2 (en) Antisense therapy for hormone-regulated tumors
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
Sikora et al. Genetic drug activation strategies for breast cancer
HK1157812A (en) Method for inhibiting the expression of a target gene and medicine for treating a tumour illness
HK1146546A (en) Method for inhibiting the expression of a target gene and medicine for treating a tumour illness